GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kala Bio Inc (NAS:KALA) » Definitions » Cash Flow from Investing

Kala Bio (Kala Bio) Cash Flow from Investing : $-0.43 Mil (TTM As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Kala Bio Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Kala Bio spent $0.01 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Kala Bio spent $0.01 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Kala Bio Cash Flow from Investing Historical Data

The historical data trend for Kala Bio's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kala Bio Cash Flow from Investing Chart

Kala Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only -1.34 -78.21 70.80 62.72 -0.43

Kala Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 -0.11 -10.03 9.72 -0.01

Kala Bio Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Kala Bio's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Kala Bio's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kala Bio  (NAS:KALA) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Kala Bio's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $-0.01 Mil. It means Kala Bio spent $0.01 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Kala Bio's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Kala Bio gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Kala Bio's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Kala Bio spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Kala Bio's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Kala Bio gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Kala Bio's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Kala Bio spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Kala Bio's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Kala Bio gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Kala Bio's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Kala Bio paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Kala Bio's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Kala Bio paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Kala Bio's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Kala Bio paid $0.00 Mil for other investing activities.


Kala Bio Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Kala Bio's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Kala Bio (Kala Bio) Business Description

Traded in Other Exchanges
Address
1167 Massachusetts Avenue, Arlington, MA, USA, 02476
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Executives
Todd Bazemore officer: Chief Operating Officer C/O DYAX CORP., 55 NETWORK DRIVE, BURLINGTON MA 01803
Romulus K Brazzell officer: Chief Medical Officer C/O INSPIRE PHARMACEUTICALS, INC., 4222 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Eric Trachtenberg officer: See Remarks 1414 RALEIGH ROAD, SUITE 400, CHAPEL HILL NC 27517
Darius Kharabi officer: CHIEF BUSINESS OFFICER C/O KALA PHARMACEUTICALS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN MA 02472
Mark T Iwicki director, officer: Chief Executive Officer 84 WATERFORD DRIVE, MARLBOROUGH MA 01752
Mary Reumuth officer: Chief Financial Officer 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Marjan Farid director C/O KALA PHARMACEUTICALS, INC., 1167 MASSACHUSETTS AVENUE, ARLINGTON MA 02476
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Mark S. Blumenkranz director C/O 1LIFE HEALTHCARE, INC., ONE EMBARCADERO CENTER, SUITE 1900, SAN FRANCISCO CA 94111
Hongming Chen officer: Chief Scientific Officer 100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
C. Daniel Myers director 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Gregory Grunberg director 100 BEAVER STREET, WALTHAM MA 02453
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116